Form 8-K - Current report:
SEC Accession No. 0001193125-25-005160
Filing Date
2025-01-13
Accepted
2025-01-13 12:25:31
Documents
15
Period of Report
2025-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d900352d8k.htm   iXBRL 8-K 28363
2 EX-99.1 d900352dex991.htm EX-99.1 34115
6 GRAPHIC g900352g0113170840506.jpg GRAPHIC 5764
  Complete submission text file 0001193125-25-005160.txt   198369

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA srpt-20250113.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE srpt-20250113_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srpt-20250113_pre.xml EX-101.PRE 10812
17 EXTRACTED XBRL INSTANCE DOCUMENT d900352d8k_htm.xml XML 3503
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 25525566
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)